STRO - ストゥロ・バイオファ―マ (Sutro Biopharma Inc.) ストゥロ・バイオファ―マ



symbol STRO
会社名 Sutro Biopharma Inc (ストゥロ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sutro Biopharma Inc. is a clinical stage drug discovery development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform XpressCF to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities including cytokine-based immuno-oncology (I/O) therapeutics antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.   ストゥロ・バイオファ―マは米国のバイオ医薬品企業。独自プラットフォ―ムであるXpressCFを介し、がん及び自己免疫疾患のためのタンパク質治療薬の新規開発・製造に焦点をあて事業を行う。主な製品候補には、多発性骨髄腫及び非ホジキンリンパ腫の治療薬STRO-001やSTRO-002のほか、卵巣がん及び子宮内膜がんの治療薬BCMA ADCがある。   Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
本社所在地 310 Utah Avenue Suite 150 South San Francisco CA 84080 USA
代表者氏名 William J. Newell ウィリアム・J.・ニューエル
代表者役職名 CEO Director
電話番号 +1 650-392-8412
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear 2018年
EBITDA EBITDA(百万ドル) -35.34900
終値(lastsale) 14.6
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 319.72020
売上高 売上高(百万ドル) 33.03600
企業価値(EV) 企業価値(EV)(百万ドル) 445.62320
当期純利益 当期純利益(百万ドル) -40.34900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sutro Biopharma Inc revenues decreased 62% to $11.5M. Net loss increased from $2.9M to $23.6M. Revenues reflect Collaboration revenue decrease of 77% to $7M. Higher net loss reflects General and administrative increase of 16% to $8.1M (expense) Research and development increase of 4% to $26.7M (expense) Interest Expense increase from $0K to $784K (expense).



   Chesterfield woman handed Slavery and Trafficking Risk Order to prevent exploitation  2020/08/05 18:26:04 Derbyshire Times
A Chesterfield woman has been handed Slavery and Trafficking Risk Order (STRO) to prevent her exploiting people into forced labour.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ストゥロ・バイオファ―マ STRO Sutro Biopharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)